The Cancer Research UK Cambridge Research Institute (CRI) is a major new cancer research initiative in the UK. The aim is to bring the scientific strengths of Cambridge to bear on practical questions of cancer diagnosis, treatment and prevention.
CRI aims to be the focus for the practical application of high-quality basic research, forming a bridge between the world-class science of the University of Cambridge and its environment, and the Addenbrooke's Hospital.
The Institute is also the nucleus of the wider virtual Cambridge Cancer Centre. This virtual Centre will bring together research groups from many disciplines (including for example, chemistry, mathematics and physics) across the University and local biotechnology companies under one umbrella to work on cross-disciplinary projects and share resources.
The Institute is housed in the custom-built £50 million Li Ka Shing Centre, located on the Cambridge Biomedical Campus. An additional £15 million has been spent on capital investment and infrastructure.
Scientists at the Institute have strong on-site administrative and core scientific services support such as genomics, bioinformatics, imaging and microscopy, histopathology and in situ hybridisation facilities. In addition, researchers have access to Cancer Research UK's national central research services.
The Cambridge Research Institute is also a member of the Organisation of European Cancer Institutes (OECI).
Management of the Cambridge Research Institute is led by the Director of the Institute, Bruce Ponder. As well as running his own research group, Professor Ponder is responsible for fostering multi-disciplinary relationships between CRI, University of Cambridge and Addenbrooke's Hospital, and directing the Institute's research strategy.
|Name:David A Tuveson|